Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission

References

• Giebel S, Labopin M, Socié G, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(1):139–149.
   PubMed Web of Science ®Google Scholar
• Brown PA, Wieduwilt M, Logan A, et al. Guidelines insights: acute lymphoblastic leukemia, Version 1.2019. J Natl Compr Canc Netw. 2019;17(5):414–423.
   PubMed Web of Science ®Google Scholar
• Giebel S, Boumendil A, Labopin M, et al. Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Ann Hematol. 2019;98(10):2389–2398.
   PubMed Web of Science ®Google Scholar
• Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(1):755.
   PubMedGoogle Scholar
• Brammer JE, Saliba RM, Jorgensen JL, et al. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017;52(1):20–27.
   PubMed Web of Science ®Google Scholar
• Czyz A, Nagler A. The Role of Measurable Residual Disease (MRD) in hematopoietic stem cell transplantation for hematological malignancies focusing on acute leukemia. Int J Mol Sci. 2019;20(21):5362.
   Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Giebel S, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24(1):337–348.
   PubMed Web of Science ®Google Scholar
• Pavlů J, Labopin M, Niittyvuopio R, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12(1):108.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–1833.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–1876.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [published correction appears in. J Clin Oncol. 2009;27(6):911–918.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–4086.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Chen Q, et al. Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years. Ann Hematol. 2019;98(4):997–1007.
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang Q, Xu LP, et al. Allogeneic Stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(4):741–750.
   PubMed Web of Science ®Google Scholar
• Zhang WP, Yang D, Song XM, et al. Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden. Biol Blood Marrow Transplant. 2013;19(4):653–660.
   PubMed Web of Science ®Google Scholar
• Wang R, Huang A, Chen Q, et al. Pulmonary infection within 100 days after transplantation impaired platelet recovery in patients with hematologic malignancies: a propensity-score-matched analysis. Ann Transplant. 2019;24:541–552.
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Zhang MJ, Wang HL, et al. Pretransplant consolidation is not beneficial for adults with all undergoing myeloablative allogeneic transplantation. Biol Blood Marrow Transplant. 2018;24(5):945–955.
   PubMed Web of Science ®Google Scholar
• Advani AS, Jin T, Ramsingh G, et al. Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49(8):1560–1566.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Labopin M, Polge E, et al. Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia. 2003;17(8):1596–1599.
   PubMed Web of Science ®Google Scholar
• Yeshurun M, Labopin M, Blaise D, et al. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120(6):855–863.
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Söderhäll S, Arvidson J, et al. Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(4):e26909.
   Web of Science ®Google Scholar
• Saarinen-Pihkala UM, Heilmann C, Winiarski J, et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol. 2006;24(36):5750–5762.
   PubMed Web of Science ®Google Scholar
• Inaba H, Pei D, Wolf J, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017;28(2):386–392.
   PubMed Web of Science ®Google Scholar
• Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–3738.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012 ;366(15):1371–1381.
   PubMed Web of Science ®Google Scholar